inverse agonist

An inverse agonist is a substance that binds to the same receptor site as an agonist but drives the receptor in the opposite direction — suppressing its activity below the level it maintains on its own, without any drug present.

This distinguishes it from a straightforward antagonist, which blocks a receptor and holds it at baseline. An inverse agonist does not simply stop signalling; it actively pulls it downward. The distinction matters because a receptor's resting state is not always neutral — many receptors maintain a low level of spontaneous activity, and inverse agonists reduce even that.

How it works · its role

Receptors can exist in two broad conformations: active and inactive. An agonist stabilises the active shape; an inverse agonist stabilises the inactive one. When enough inverse agonist is bound, the receptor population shifts toward the inactive state, producing effects that are qualitatively the reverse of what a full agonist would cause at the same site.

Because the effect depends on there being some baseline receptor activity to suppress, inverse agonism is most pronounced when a receptor system is tonically active — running at some baseline level even without a drug driving it. The stronger that baseline activity, the larger the observable inverse effect.

Relevance to substances & effects

The concept is most familiar in the context of GABA-A receptors, the primary target of benzodiazepines and alcohol. Classic benzodiazepines are positive allosteric modulators — they enhance the receptor's response to GABA, producing sedation, anxiolysis, and muscle relaxation. Certain beta-carboline compounds act as inverse agonists at the same site, producing the opposite cluster: anxiety, hyperexcitability, and elevated muscle tension.

Antihistamines offer a widely encountered example. Many H1-receptor antihistamines — including common over-the-counter sleep aids — function as inverse agonists rather than simple antagonists, actively suppressing constitutive H1 signalling. The sedation and cognitive blunting they produce partly reflect this mechanism.

Some antipsychotic drugs have inverse agonist or partial inverse agonist properties at dopamine D2 receptors, reducing dopamine tone below baseline. This can contribute to the flattening of motivation and reward response sometimes associated with long-term antipsychotic use, a recognised clinical concern separate from the intended therapeutic effect.

Understanding whether a drug is an antagonist or an inverse agonist at a given receptor helps explain why two drugs that both block a site can feel entirely different. One may simply silence incoming signals; the other actively reverses the baseline state.